Fig. 5.

MGMT promoter methylation level in initial tumors predicts hypermutation status at recurrence. (A) Methylation level at each CpG site for initial tumors and recurrences of patients by HM status. (B) Average methylation level for initial tumors and recurrences of patients by HM status. (C) Paired analysis of average methylation level between initial tumors and recurrences. (D) Change in average MGMT promoter methylation level from initial tumor to recurrence. (E) Regression tree identifying average methylation level in initial tumors as a significant predictor of HM status at recurrence.